Zentalis Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Zentalis Pharmaceuticals, Inc. reported a net loss of $137.1 million for 2025, narrowing from $165.9 million in 2024, as it strategically restructured to prioritize its lead oncology candidate, azenosertib, and extend its cash runway into late 2027.
NASDAQ
Zentalis Pharmaceuticals focuses on advancing azenosertib, a WEE1 inhibitor, for ovarian cancer treatment while managing financial resources.
NASDAQ
10-K: Zentalis Pharmaceuticals Inks Employment Agreement with New Chief Medical Officer, Diana Hausman
Zentalis Pharmaceuticals has formalized an employment agreement with Diana Hausman, M.D., as its new Chief Medical Officer, effective January 19, 2024.